Inclusion Criteria:

          -  Histological/cytological diagnosis of primary HCC, excluding cholangiocarcinoma,
             hepatocholangiocarcinoma, fibrolamellar carcinoma and hepatoblastoma

          -  Advanced stage HCC per EASL-EORTC (European Association for the Study of the
             Liver-European Organisation for Research and Treatment of Cancer) guidelines, i.e.
             patients who are not candidates for curative interventions and not candidates for
             locoregional modalities

          -  Patients naïve to systemic therapy for HCC

          -  Tumor status (as determined by radiology evaluation): At least one measurable viable
             tumor in the liver, ≥1 cm longest diameter (LD), using a dynamic imaging technique
             (arterial phase of triphasic computerized tomography [CT] scan, or dynamic
             contrast-enhanced magnetic resonance imaging [MRI]), and injectable under
             imaging-guidance (CT or ultrasound)

          -  At least one tumor that has not received prior local-regional treatment, or that has
             exhibited definitive growth of viable tumor since prior local-regional treatment of
             HCC undertaken at least 4 weeks prior to enrolment or 3 months prior to enrolment for
             radioembolization

          -  Child-Pugh Class A. Note: paracentesis, albumin infusion or diuretic treatment cannot
             be used to downgrade Child-Pugh score (e.g., to improve from severe to moderate/mild
             or from moderate to mild ascites)

          -  Performance status 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale

          -  Adequate hematological, hepatic, and renal function

          -  Additional inclusion criteria exist

        Exclusion Criteria:

          -  Histological diagnosis of cholangiocarcinoma, hepatocholangiocarcinoma, fibrolamellar
             carcinoma and hepatoblastoma

          -  Symptomatic cardiovascular disease, including but not limited to significant coronary
             artery disease (e.g., requiring angioplasty or stenting) or congestive heart failure
             within the preceding 12 months

          -  Current or past history of cardiovascular disease (e.g., past history of myocardial
             infarction, ischemic cardiomyopathy) unless cardiology consultation and clearance has
             been obtained for study participation

          -  History of moderate or severe ascites, bleeding esophageal varices, hepatic
             encephalopathy or pleural effusions related to liver insufficiency within 6 months of
             screening; patients with adequately treated esophageal varices are allowed

          -  Active, known or suspected significant immunodeficiency due to underlying illness
             including HIV/AIDS, autoimmune diseases, and/or immune-suppressive medication
             including high-dose corticosteroids

          -  History of severe eczema and/or ongoing severe inflammatory skin condition (as
             determined by the Investigator) requiring medical treatment

          -  Any known allergy or reaction to any component of nivolumab formulation or its
             excipients

          -  Additional exclusion criteria exist